Clinical Care Options (CCO), a leader in education for healthcare professionals, will provide official online scientific analysis of the XVIII International AIDS Conference in Vienna, Austria, July 18-23, 2010.
"We continue to be impressed with CCO's coverage of our conferences and are pleased that this resource will once again be available," said Mats Ahnlund, Acting Executive Director of the International AIDS Society (IAS), which convenes the conference in collaboration with international, regional and local partners. "The scientific analysis of the clinical data presented in Vienna is an invaluable service to meeting delegates as well as those unable to attend. In our view, this coverage is an important way of disseminating new knowledge and information about the latest scientific developments, thereby strengthening the global response to HIV."
AIDS 2010 will be the fifth time that CCO has produced official coverage of a conference convened by the IAS. Coverage will include summaries and audio highlights of important data presented, as well as an Expert Analysis of the impact of those data on the care of people living with HIV around the world. CCO's original online point-of-care resource, CCO HIV inPractice, will also be updated following the meeting to reflect the new data.
"We are honored to have this continuing opportunity to deliver critical new information and educational resources from this important international scientific meeting," said Jeffrey L. Drezner, MD, PhD, CCO's Chief Executive Officer and Founder. "HIV clinicians worldwide will benefit from the analyses by our faculty experts, resulting in improved patient care."
In cooperation with the Kaiser Family Foundation, a leader in health policy and communications, NAM, an award-winning community-based HIV information provider, and CCO, the conference website will offer comprehensive coverage of the meeting, including a new conference blog. The organizations' Web sites also will be linked and integrated to bring full coverage to clinicians around the world.
Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic